EQUITY RESEARCH MEMO

DNA Link

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)55/100

DNA Link, operating as JS Link Sequencing Lab, is a US-based genomic research services company with its primary laboratory in Seoul, South Korea. Founded in 2000, the company provides comprehensive next-generation sequencing (NGS) and genomic analysis solutions to researchers globally. Leveraging a multi-platform infrastructure, DNA Link enables large-scale and technically challenging projects, including population genomics and novel genome assemblies. The company targets academic, pharmaceutical, and biotechnology clients, offering end-to-end services from sample preparation to data analysis. Despite being privately held and lacking disclosed financials, DNA Link has established a presence in the competitive genomics services market, differentiating through its focus on complex, high-throughput sequencing and its dual US-Korea operational base.

Upcoming Catalysts (preview)

  • Q4 2026Major contract award for population-scale genomics project40% success
  • 2026Strategic partnership or acquisition by larger life sciences tools company30% success
  • Q2 2027Launch of new proprietary sequencing analysis platform20% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)